A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
NK/T Cell Lymphoma Nos
DRUG: Toripalimab|DRUG: Pegaspargase|DRUG: Gemcitabine|DRUG: Oxaliplatin|RADIATION: Definitive intensity-modulated radiotherapy (IMRT)
progression free survival (PFS), 3 years
complete remission (CR) rate, From the start of treatment with the interventions until 6 months|overall response rate (ORR), From the start of treatment with the interventions until 6 months|overall survival (OS), 3 years|recurrence-free survival (RFS), 3 years|event free survival (EFS), 3 years|disease-free survival (DFS), 3 years
The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)